Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Positive Skin Prick test to grass pollen~* Positive RAST to grass pollen~* Positive specific provocation test to grass pollen~Exclusion Criteria:~* Serious chronic diseases~* Other perennial allergies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Allergovit 6-grasses immunotherapy (Type: EXPERIMENTAL): Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo injections was given the same way: Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.

Based on this trial design, predict the completion outcome and termination type (if applicable).